Definium Therapeutics (NASDAQ:DFTX) Reaches New 12-Month High – Here’s Why

Definium Therapeutics, Inc. (NASDAQ:DFTX) hit a new 52-week high on Monday . The stock traded as high as $47.20 and last traded at $46.81, with a volume of 3469289 shares traded. The stock had previously closed at $44.95.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on DFTX. Leerink Partners set a $52.00 price objective on Definium Therapeutics and gave the company an “outperform” rating in a research report on Monday, June 22nd. Needham & Company LLC boosted their target price on Definium Therapeutics from $38.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, June 23rd. Oppenheimer set a $60.00 target price on Definium Therapeutics and gave the company an “outperform” rating in a research report on Monday, June 22nd. Robert W. Baird raised their price target on Definium Therapeutics from $37.00 to $57.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 23rd. Finally, Citigroup reaffirmed a “buy” rating on shares of Definium Therapeutics in a research note on Monday, June 22nd. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Definium Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $47.08.

Definium Therapeutics Stock Up 3.6%

The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.15. The company has a 50-day simple moving average of $24.59 and a 200 day simple moving average of $19.41. The company has a market cap of $4.64 billion, a P/E ratio of -18.69 and a beta of 2.37.

Definium Therapeutics (NASDAQ:DFTX) last released its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.23). On average, equities analysts anticipate that Definium Therapeutics, Inc. will post -2.29 EPS for the current year.

Insider Activity at Definium Therapeutics

In related news, CEO Robert Barrow sold 29,208 shares of Definium Therapeutics stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $1,315,236.24. Following the completion of the sale, the chief executive officer owned 1,098,246 shares in the company, valued at $49,454,017.38. This trade represents a 2.59% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Brandi Roberts sold 3,013 shares of the business’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $135,675.39. Following the completion of the sale, the chief financial officer directly owned 209,487 shares of the company’s stock, valued at approximately $9,433,199.61. This trade represents a 1.42% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 48,096 shares of company stock worth $2,165,763. 2.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Definium Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Cerity Partners LLC lifted its holdings in shares of Definium Therapeutics by 2.4% in the 2nd quarter. Cerity Partners LLC now owns 49,650 shares of the company’s stock worth $322,000 after buying an additional 1,165 shares during the period. Creative Planning raised its holdings in shares of Definium Therapeutics by 2.6% in the second quarter. Creative Planning now owns 66,097 shares of the company’s stock valued at $429,000 after acquiring an additional 1,655 shares in the last quarter. Bay Rivers Group lifted its stake in Definium Therapeutics by 14.3% in the fourth quarter. Bay Rivers Group now owns 16,001 shares of the company’s stock worth $214,000 after acquiring an additional 2,000 shares during the period. Rathbones Group PLC lifted its stake in Definium Therapeutics by 7.1% in the third quarter. Rathbones Group PLC now owns 30,200 shares of the company’s stock worth $356,000 after acquiring an additional 2,000 shares during the period. Finally, Russell Investments Group Ltd. grew its holdings in Definium Therapeutics by 110.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after acquiring an additional 2,003 shares in the last quarter. 27.91% of the stock is owned by institutional investors.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.